Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
February 03, 2025 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
cmi_logo.png
[Latest] Global Artificial Intelligence in Banking Market Size/Share Worth USD 140,940.1 Million by 2033 at a 22.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value)
January 21, 2025 09:30 ET | Custom Market Insights
Austin, TX, USA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Artificial Intelligence in Banking Market Size, Trends and Insights By Component...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
January 08, 2025 09:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of...
Full name logo.png
Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
December 18, 2024 08:30 ET | Remedy Plan Therapeutics
Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
Quantexa-logo-positive-RGB.png
Quantexa Recognized as Category Leader in Chartis’ 2024 AML Transaction Monitoring Solutions Report
December 16, 2024 03:00 ET | Quantexa
Quantexa today announced recognition in Chartis’ RiskTech Quadrant Update for anti-money laundering (AML) transaction monitoring solutions.
Biomea-Fusion_Logo_RGB_rev2_Email.png
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
December 09, 2024 16:01 ET | Biomea Fusion, Inc.
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and tolerability...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
December 09, 2024 07:30 ET | Vor Biopharma
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to...
Biomea-Fusion_Logo_RGB_rev2_Email.png
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
December 06, 2024 08:00 ET | Biomea Fusion, Inc.
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...